Kornimate/medical-research-clean huggingface dataset:
artemether-lumefantrine effectiveness in guinea-bissau 2

Conditions: Malaria

Summary: the routine treatment of children with antimalarials will be monitored. children with a positive malaria film and/or a positive rapid diagnostic test (rdt) will have a capillary blood sample taken to verify the diagnosis and to monitor the pattern of resistance.

children from bissau seeking medical advice and who are recommended treatment for malaria in accordance with the current routines will be included as follows: all children getting the clinical diagnosis of malaria will be registered and basic information collected. all children with a positive malaria film and/or a positive rdt will be asked for a capillary blood sample (app. 50 - 100 microliters on a filterpaper). using pcr the parasitological diagnosis will be verified and if parasites are identified the resistance patterns will be examined. both the capillary blood samples and the rdts (if taken by the health staff) will be used in order to examine whether the rdts can be used for routine monitoring of resistance in an area. the study does not interfere in the routine treatment of the health staff. none of the children will be followed.

Eligibility criteria:
inclusion criteria: * children seeking a health centre and by the health staff given the diagnosis: malaria and/or being treated with an antimalarial. exclusion criteria: * children where the parents do not accept to participate in the study.
precise use of lidocaine cream to treat primary premature ejaculation

Conditions: Premature Ejaculation

Summary: this study aimed to evaluate the efficacy and safety of applying 5% lidocaine cream to the sensitive area of the glans penis after its precise localization under the penile biological vibration threshold test for the treatment of primary premature ejaculation.

this study was a randomized, single-blind clinical controlled trial. eighty patients diagnosed with primary premature ejaculation in an outpatient setting were included in this study. they were randomly scored into two groups. group 1 (n = 40) was given 1 ml of 5% lidocaine cream on demand. they were instructed to apply the lidocaine cream evenly in a circular pattern to the glans penis without precise application to the sensitive area of the glans penis. the treatment lasted for a total of 4 weeks. group 2 (n = 40) had a penile biological vibration threshold test performed to detect loci with a lower threshold. they were instructed to apply 1 ml of 5% lidocaine cream to the sensitive loci on the glans penis for 4 weeks. lidocaine cream was applied topically or uniformly to the glans penis 20 minutes before planned intercourse in both groups and washed off 10 minutes after application. using intravaginal ejaculation before and after treatment latency, the arabic index of premature ejaculation, premature ejaculation diagnostic tool, and the international index of erectile function scale scores were combined to assess the efficacy and side effects before and after treatment.

Eligibility criteria:
inclusion criteria: * adult male (19-60 years old); stable partner for ≥3 months; premature ejaculation diagnostic tool (pedt) score ≥ 11; penile biological vibration threshold test suggesting the presence of sensitive sites on the glans penis (vibration threshold \< 30 levels); no history of long-term use of specific medications; normal sex hormone levels; and no genital or secondary ejaculation. there was no history of long-term use of specific drugs, normal sex hormone levels, and genital or secondary sexual characteristics abnormalities. exclusion criteria: * (1) those with abnormal or malformed genital development; (2) those with allergic reactions to local anesthetics; (3) those who had been treated with central nervous system drugs or pe in the last 3 months; (4) those with a history of long-term alcohol abuse and trauma such as neurological and pelvic fractures; (5) those with long-term use of hypotensive drugs, diuretics, and sedative drugs (6) patients with a history of previous surgery and trauma to the reproductive system; (7) patients with pe due to hypogonadism, thyroid disease, and abnormal lipid metabolism.

Keywords: primary premature ejaculation; lidocaine; arabic index of premature ejaculation
identifying ultrasonic diagnostic characteristics of cervical lymphadenopathy: a retrospective, multicenter study

Conditions: Lymph Node Disease; Ultrasound Therapy; Complications

Summary: the observed indexes of the four cervical lymph node diseases were identified by informatics methods, and the differences in the diagnosis of the four diseases were evaluated, so as to improve the clinical diagnosis rate and provide a research basis for the ultrasonic evaluation of the surgical indications of cervical lymph node diseases in the future.


Eligibility criteria:
inclusion criteria: * patients with one of these four diseases exclusion criteria: * 1. patients with severe heart and brain diseases and poor coagulation function. 2. undiagnosed patients are not included in the statistical analysis. 3. image distortion of ceus acquisition cannot be analyzed.
treatment by insulin continuous infusion in type 2 diabetes

Conditions: Diabetes

Summary: the aim of the tricidia2 study is to compare two modalities of administration of insulin. in our future study, the investigators wish to study if the treatment by continuous infusion of insulin improves the insulinosensitivity of type 2 diabetic patients; the investigators indeed expect that the insulin delivered in a continuous way decreases the insulino-resistance of these patients compared with the intermittent delivering of insulin.

we wish to use before and after treatment the classic tools of measure of insulinosensitivity / the euglycemic hyperinsulinemic clamp associated with a measure of the insulinosecretion thanks to a test of load in glucose iv. the coupling in the same procedure of these 2 tests is the botnia clamp. we also wish to use the continuous measure of subcutaneous glucose during several days to estimate the reduction in the average glycemia on the fast and prandial periods as well as the decrease of the time spent in hyperglycemia during the day. this tool demonstrated its interest in type 2 diabetic population in several studies. finally the current / spectro-irm methods of imaging are now validated to quantify and measure exactly the importance of the steatosis, including in type 2 patients, because we know that it is probably the result of the insulino-resistance; we would also like to demonstrate that some genetic polymorphisms of proteins (polymorphisms g / t493 of the mtp, 1927 c/t of the receiver r1 of the adiponectin and 265 c/t of the gene of apolipoprotéines a) are factors which can modulate the steatosis development in case of type 2 diabetes. in other secondary criteria we wait for an improvement of hba1c, quality of life of type 2 obese people with regard to the treatment by intensified multi-injections.

Eligibility criteria:
inclusion criteria: * age \> 18 years old * type 2 diabete patient with insuline basal/bolus treatment for at least 6 months * doses of insuline \> 0,7 u/kg/j * hba1c ≥ 7,5% * without ado for at least 4 weeks (sulfamides, incrétines, glinides, acarbose) except the metformine * bmi ≥ 28,5 kg/m² * clinical diagnostique of diabetes for at least 10 ans * patient must be able to realize an automonitoring and to manage the functioning of an insulin pump. exclusion criteria: * glitazone treatment less than 3 month before inclusion * patient with an untreated by the laser proliferative ischemic retinopathy * bmi \< 28,5 kg/m² * pacemaker (ci irm) * presence of implantable material (ci irm) * pregnancy, breast-feeding * practices of violent sports * professional extreme environment of cold or heat * serious psychiatric diseases physical and/or psychiatric incapacitated medically significant * poor sanitation
efficacy of infliximab as a rescue therapy in pediatric acute severe colitis

Conditions: Pediatric Acute Severe Colitis

Summary: background and aims: acute severe ulcerative colitis (asc) is a potentially life-threatening event. poor pediatric data are available about the success rates of infliximab (ifx) as a second line therapy. this study was performed in consecutively observed pediatric patients with asc, treated according to the 2011 european crohn's colitis organization (ecco)- european society for pediatric gastroenterology, hepatology and nutrition (espghan) guidelines on pediatric asc¹ and aim to assess the long-term efficacy of ifx and clinical predictors of poor outcome. methods: children hospitalized for an episode of asc, defined as a pediatric ulcerative colitis activity index (pucai) of at least 65 points, were enrolled. clinical assessment through pucai and laboratory data (erythrocyte sedimentation rate, c-reactive protein, hemoglobin, albumin, hematocrit, ferritin) was recorded at admission and at day 3 and 5. all patients were treated according to the above mentioned guidelines for asc and received intravenous (iv) corticosteroids (cs) as first-line therapy. ifx was administered as second-line therapy in cs-refractory patients. in a 2-year follow up the overall colectomy rate and the efficacy of ifx in avoiding colectomy were evaluated.


Eligibility criteria:
inclusion criteria: * diagnosis of asc * confirmed diagnosis of ulcerative colitis (uc) * age 1-18 years exclusion criteria: * not confirmed diagnosis of uc * contraindications for infliximab therapy

Keywords: acute severe colitis children infliximab colectomy
effect of immersion level on respiratory function of spinal cord injury patients during balneotherapy

Conditions: Spinal Cord Injury

Summary: balneotherapy is a physiotherapy technique which allows patients to work out in a weightless environment and which is often used in patients with spinal cord injury. in normal subjects, water immersion generates a reduction in lung volumes. the effects of water immersion on the respiratory function of spinal cord injury patient (who are liable to present a respiratory failure secondary to paralysis) are not well known. they could be deleterious (by majoring respiratory failure)or beneficial (by mimicking the effect of a corset and improving respiratory function). therefore, we are planning to study the effect of different water immersion levels on the respiratory function of spinal cord injury patients.


Eligibility criteria:
inclusion criteria: * adult patient * complete tetraplegia from spinal cord injury * initial spinal cord injury at leat 3 months before study exclusion criteria: * contra indication to a balneotherapy session (bed-sore, skin infection or irritation, urinary or fecal incontinency, tracheostomy, ongoing infection) * unstable respiratory state (patient free of respiratory infection or encumbrance) * refusal to participate to the protocol * pregnancy

Keywords: lung function water immersion balneotherapy
latanoprost for the treatment of menière's disease

Conditions: Menière's Disease

Summary: the purpose of the study is to evaluate the dose regimen, efficacy and safety of latanoprost for the treatment of menière's disease.


Eligibility criteria:
inclusion criteria: * at least 18 years of age * definitive unilateral menière's disease (aao-hns 1995) * disease stage ii - iii: pta4 (pure tone average) (0.5, 1.0, 2.0 and 3.0khz) between 25db and 70db * speech discrimination score in silence: no better than 85% * at least three vertigo attacks (lasting ≥ 20 minutes) during the last three months prior to inclusion * tinnitus during the last three months prior to inclusion * signed written informed consent exclusion criteria: * medical or psychiatric conditions which could jeopardize or would compromise the subject's ability to participate in the trial or decrease the likelihood of obtaining satisfactory data to achieve the objective of the trial, dementia, alcohol or substance abuse. * bilateral menière's disease * chronic otitis media on the ear affected by menière's disease * subjects not fluent in swedish language * bronchial asthma * previous intratympanic injection of gentamicin or surgical therapy * previous intratympanic steroid therapy less than six months prior to inclusion * known hypersensitivity to local anesthetics * pregnant women * nursing mothers

Keywords: menière's disease vertigo hearing loss tinnitus
efficiency of different exercise approaches in individuals providing primary care to ms

Conditions: Back Pain

Summary: multiple sclerosis is known as an inflammatory central nervous system disease characterized by demyelination and axonal damage.

individuals with ms cannot perform self-care in many areas due to the problems they encounter during their daily life activities, and they need an individual who will take care of them and a lifelong care.

Eligibility criteria:
inclusion criteria * chronic low back pain he is 18-60 years old * no verbal communication barrier * complaining of pain for more than three months * volunteering of participants exclusion criteria * absence of cognitive impairment (delirium, dementia, amnesia) * exercise contraindications (uncontrolled medical conditions) * caring for individuals with an unclear diagnosis of ms * disagreeing with the measurements to be made or providing incomplete answers * previous spinal surgery * spinal and joint disorders other than lumbar disc herniation

Keywords: back pain multiple sclerosis
post-market surveillance study of alk-positive advanced nsclc participants treated with iruplinalkib

Conditions: NSCLC

Summary: the goal of this observational study is to evaluate the safety and efficacy of participants diagnosed with anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc) who are being treated with iruplinalkib or planned to receive iruplinalkib treatment in real-world clinical practice.


Eligibility criteria:
inclusion criteria: * pathologically confirmed patients with locally-advanced or metastatic alk-positive non-small cell lung cancer. * currently receiving, or planned to receive treatment with iruplinalkib. * subjects had imaging reports of chest and abdominal enhanced ct and brain mri within 42 days prior to the first dose of iruplinalkib as 1l treatment for locally-advanced or metastatic alk-positive non-small cell lung cancer. * subjects had routine and biochemical reports within 30 days prior to the first dose of iruplinalkib as 1l treatment for locally-advanced or metastatic alk-positive non-small cell lung cancer. exclusion criteria: * patients who had previously been treated with alk-tki, but who had previously only been treated with alk-tki as neoadjuvant and/or adjunctive treatment could be enrolled. * mental disorder or inability to cooperate with examination or follow-up. * women known to be pregnant or lactating.
effect of biological disease modifying anti rheumatic drug (bdmard) treatment on spinal fracture incidence in patients with ankylosing spondylitis (as)

Conditions: Ankylosing Spondylitis; Spinal Fractures

Summary: ankylosing spondylitis (as) is a rheumatoid disease affecting all segments of the axial skeleton, leading to the complete fusion of all spinal segments - the bamboo-spine. during the last decade biological disease modifying anti-rheumatic drugs (bdmard) have been successfully introduced to reduce the disease activity. it is unclear whether bdmard treatment had an effect on spinal fracture risk related to as. this national registry study will investigate the effect of bdmard treatment on spinal fracture risk in a national cohort of patients with as.


Eligibility criteria:
inclusion criteria: * age 30-60 years * registered diagnosis of ankylosing spondylitis exclusion criteria: * age \ 60 years
study of hbv therapeutic vaccines gs-2829 and gs-6779 in healthy participants and participants with chronic hepatitis b

Conditions: Chronic Hepatitis B

Summary: the goal of this clinical study is to learn more about gs-2829 and gs-6779 in healthy participants and participants with chb.


Eligibility criteria:
key inclusion criteria: phase 1a and 1b: * body mass index (bmi) of ≤ 32.0 kg/m\^2. * non-diabetic without impaired glucose tolerance. * no evidence of cardiac disease based on 12 lead ecg. phase 1a (healthy individuals) only: * aged 18 through 60 years. * no history of hepatitis b infection with a negative hepatitis b virus (hbv) core antibody. phase 1b (virally suppressed chb individuals): * aged 18 through 65 years. * documented chb and hbsag ≤ 5000 iu/ml at screening. * no evidence of advanced fibrosis by fibroscan (defined as fibroscan \< 9 kpa within 6 months of screening). * diagnosed with chronic hepatitis b on suppressive oral antiviral for ≥ 6 months. key exclusion criteria: phase 1a and 1b: * use of any systemic antibiotics within 30 days of screening. * receipt of any hbv vaccine within 12 months of screening visit or planning hbv vaccination during the study period. * receipt of any investigational product within 3 months or vaccine within 3 months of screening (with the exception of influenza and severe acute respiratory syndrome coronavirus 2 (sars-cov-2) vaccines, which if needed, should be administered at least 14 days before or after an investigational product administration). * receipt of immunoglobulin or other blood products within 3 months of screening. * positive serum pregnancy test at screening or positive urine pregnancy on day 1. * have been treated with systemic steroids, immunosuppressant therapies, or chemotherapeutic agents within 3 months prior to screening or is expected to receive these agents during the study (eg, corticosteroids, immunoglobulins, other immune or cytokine-based therapies). * participation in any other clinical study (including observational studies) without prior approval from the sponsor is prohibited while participating in the study. note: other protocol defined inclusion/exclusion criteria may apply.
investigating multigene methylation dynamics in treatment response surveillance for gastric cancer

Conditions: Gastric (Stomach) Cancer

Summary: the primary objective is to determine whether pretreatment-to-posttreatment changes in circulating multigene methylation levels correlate with objective response rates (orr) assessed by contrast-enhanced ct/mri and levels of serum tumor markers. secondary endpoints include: (a) time-dependent association between methylation fluctuation patterns and progression-free survival (pfs), (b) comparative diagnostic accuracy of methylation indices versus conventional biomarkers, and (c) feasibility of using methylation thresholds to guide adaptive therapy modification.


Eligibility criteria:
inclusion criteria: age at initial diagnosis: 18-75 years histologically confirmed gastric or gastroesophageal junction malignancy, with complete medical records, confirmed pathological diagnosis, and definitive staging data (tnm staging system) no history of other primary malignancies absence of distant metastases (liver, lung, or other sites) confirmed by imaging examination (ct/mri) no prior surgical resection, chemotherapy, or pd-1/pd-l1 immunotherapy before enrollment availability of complete biospecimen information, including: sample id (medical record number), demographic data (sex, age), clinical diagnostic data, tumor marker profiles (cea, ca19-9, etc.) exclusion criteria: life expectancy \<6 months (as assessed by ecog score ≥4 or palliative performance scale ≤30%) cognitive/psychiatric conditions: a. legally incapacitated individuals without legal guardians, b. active psychotic disorders (e.g., schizophrenia, bipolar disorder) or dementia (mmse score \<24) investigator-determined exclusions
effect of vibration massager therapy on non-specific low back pain

Conditions: Neck Pain

Summary: the main purpose of this study was to examine the effects of vibratory massage therapy on individuals with non-specific low back pain.

this study will be conducted using a randomized controlled design. volunteers between the ages of 18-65 with non-specific low back pain will be included in the study. inclusion criteria are that participants do not have structural pathologies and agree to participate in the study voluntarily. exclusion criteria include spinal deformities and exercise intolerance. participants will be randomly divided into two groups. individuals in the first group will receive vibratory massage therapy, while the second group will be evaluated with standard treatment methods as a control. both groups will receive treatment 3 times a week for 8 weeks. participants' quality of life, pain levels, range of motion, and muscle activity will be evaluated before and after treatment. data will be collected using tools such as sf-36, oswestry low back pain index, and vas (visual analog scale).

Eligibility criteria:
inclusion criteria: * having back pain for the last 3 months vas \>4 * between 18-65 years of age. * volunteers for the study. * not having undergone surgical intervention in the last 6 months * individuals with structural amoli (e.g. spinal deformity). * having chronic bone disease exclusion criteria: * not being able to cooperate * presence of psychological problems * use of sleeping pills, * presence of neurological and orthopedic diseases.
examining the efficiency of neurofeedback therapy on adults with sensory over responsivity

Conditions: Sensory Modulation Disorder; Sensory Over-Responsivity

Summary: sensory over-responsivity (sor) is characterized by a disruption in regulating sensory stimuli and can significantly impact pain perception and restrict daily participation and quality of life. altered neurophysiological processes in sor are documented, revealing reduced electroencephalogram at rest and p300 amplitudes, the latter tested through event-related potentials (erp). both may explain the failure to regulate incoming sensory stimuli. neurofeedback (nf) therapy, a remedial treatment approach, aims at self-regulating the brain's neural activity and has proven its efficiency in treating comorbid smd syndromes. our study aims to investigate nf therapy efficiency in decreasing pain sensitivity, enhancing auditory erp components of p300, increasing the power of the alpha band, life-satisfaction and goal attainment scaling (gas) scores in adults with sor.

in this serial experimental research design, 10 individuals with sor aged 21-45 years will participate. a medical and demographic questionnaire and the sensory responsiveness questionnaire-intensity scale (srq-is) will be applied to screen for participation eligibility. outcome measures will be conducted at 4-time points (1. baseline- 3 weeks pre-treatment; 2. before the first treatment session; 3. after the last treatment session; and 4. a month post-treatment) applying: the goal attainment scaling (gas), the p300 component using a neurophysiological assessment of the 'oddball paradigm', the alpha power using electroencephalogram resting state, and electronic versions of the satisfaction with life scale, the world health organization disability assessment schedule, and the pain sensitivity questionnaire. sixteen individually therapy sessions of 45 minutes each, twice a week, will be held at the same time of day. repeated measures anova or a non-parametric equivalent will be used to analyze the dependent variables measures change over time.

Eligibility criteria:
inclusion criteria: 1. having sor indicated by a score higher than 2.39 on the sensory responsiveness questionnaire-aversive scale. 2. free of analgesic medicines for no less than 24 hours before the sessions. 3. independent functioning in the community. 4. fluency in understanding and reading hebrew exclusion criteria: 1. metabolic, psychiatric, neurological, or neuro-developmental, but adhd diagnosis 2. acute or chronic pain. 3. regular intake of neurological, psychiatric and analgesic medicines. 4. participating in other therapies (i.e., cognitive therapies) at present. 5. substance abuse. 6. pregnancy.

Keywords: neurofeedback sensory modulation disorder sensory over-responsivity